Patients presenting with high tumor Cks1 levels had significantly shorter disease-free survival rates than patients with low Cks1 levels (54 months vs 76 months, respectively; P = 0.0007; Fig. 3a). The gene discussed is CKS1B; the disease is neoplasm.